"Rosnano" withdrew from the project of the federal network of nuclear medicine centers "PET-technology": its share in 49.9% it sold to "Pharmstandard" Victor Kharitonin for 2.9 billion rubles. As a result, the entrepreneur's structure received 100% of the network. For Rusnano, the return on investment in the transaction was 6.3%, which could be the lowest figure for the company.

The fact that Pharmstandard Group became a 100% owner of the network of nuclear medicine centers of PET Technologies LLC, having bought out 49.9% of Rusnano, a representative of the state company told Kommersant. According to him, this share was fully paid in cash in the amount of 2.9 billion rubles, which is 700 million rubles. exceeded Rusnano's investment in the project. The company added that the transaction has already been approved by the Federal Antimonopoly Service. Pharmstandard declined to comment.

The network of "PET-technology" was established with the participation of "Rusnano" in 2011. Now includes 11 nuclear medicine centers in Moscow, Kursk, Belgorod, Yekaterinburg, Ufa, Lipetsk, Orel, Tambov, Togliatti, Samara, Rostov-on-Don. The company also includes two sites for the production of radiopharmaceuticals, located in Ufa and Yelets. Total investment in the development of "PET-technology" amounted to more than 4.6 billion rubles. As early as the beginning of the year, 50.01% of the "PET-technology" belonged to Alexey Tsarkov, LLC D-honey, but in March, the final beneficiary was the structure of the owner of Pharmstandard Viktor Kharitonin.

The return on investment of "Rusnano" in "PET-technology" was 6.3%, the representative of the group said. They noted that this figure corresponds to the market indicators of profitability in medicine. Meanwhile, the level of return on investment of Rusnano at the exit from past projects was at least 16%, it follows from the materials of the company's website. The record profitability of 41.1% of "Rosnano" was received in 2013, when it sold for 2.3 billion rubles. share in the manufacturer of the antiviral drug "Kagocel" "Niarmedic Pharm". The level of profitability of 6.3% of the general director of "Infoline-Analytica" Mikhail Burmistrov considers unacceptably low for "Rosnano". But, he suggests, the indicator could be even lower if Rusnano decided to withdraw from the project later.

According to Olga Spichko, managing director for investment activities of MC Rusnano, the revenue of PET technology in 2017 was 1 billion rubles, and in 2018 it could increase 1.5 times. "This will allow the investor to continue geographic development of the network and expand the range of services provided in the field of nuclear medicine," said Ms. Shpichko. The payback period of investments of Pharmstandard in the purchase of the share of Rosnano in PET technology can exceed seven years, believes the director of the Institute of Health and Medical Management David Melik-Huseynov. "Positron emission and computed tomography are still not in high demand, as this service is new and expensive," he says. According to the expert, the desire of the owner of "Pharmstandard" to enter the market of nuclear medicine may be due to the fact that the Ministry of Health singles out this direction as one of the priority.

About Kharitonin's interest in modern medical technologies in the field of cancer treatment became known in December 2017, when an entrepreneur-like IPT Group announced plans for a decade to create a network of oncological centers for radiosurgery and radiation therapy. The IPT Group expects that each clinic will annually hold up to 4,000 operations at a cost of $ 3.5 thousand each, with 50% on federal quotas and 40% on patient funds. Investments in the project were estimated at more than $ 200 million, some of them are expected to be attracted through the ICO. The Pre-ICO was due to begin on January 9, 2018, but was postponed due to the appearance of a bill regulating the ICO in Russia.